References
Aitken ML,
Moss RB,
Waltz DA et al.
(2001)
A Phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
Human Gene Therapy
12(15):
1907–1916.
Alton EW,
Boyd AC,
Cheng SH et al.
(2013)
A randomised, double‐blind, placebo‐controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Thorax
68(11):
1075–1077.
Alton EW,
Stern M,
Farley R et al.
(1999)
Cationic lipid‐mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double‐blind placebo‐controlled trial.
Lancet
353(9157):
947–954.
Bellon G,
Michel‐Calemard L,
Thouvenot D et al.
(1997)
Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial.
Human Gene Therapy
8(1):
15–25.
Cao H,
Machuca TN,
Yeung JC et al.
(2013)
Efficient gene delivery to pig airway epithelia and submucosal glands using helper‐dependent adenoviral vectors.
Molecular Therapy – Nucleic Acids
2:
e127.
Cao H,
Yang T,
Li X‐F et al.
(2011)
Readministration of helper‐dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
Gene Therapy
18(2):
173–181.
Caplen NJ,
Alton EW,
Middleton PG et al.
(1995)
Liposome‐mediated CFTR gene transfer to the nasal epithlium of patients with cystic fibrosis.
Nature Medicine
1(1):
39–46.
Chen X,
Kube DM,
Cooper MJ and
Davies PB
(2008)
Cell surface nucleolin serves as receptor for DNA nanoparticles composed of PEGylated polylysine and DNA.
Molecular Therapy
16(2):
333–342.
Crystal RG,
McElvaney NG,
Rosenfeld MA et al.
(1994)
Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.
Nature Genetics
8(1):
42–51.
Cystic Fibrosis Foundation Patient Registry
(2013)
2012 Annual Data Report.
Bethesda, MD: Cystic Fibrosis Foundation.
Davies JC,
Davies G,
Gill D et al.
(2011)
Safety and expression of a single dose of lipid‐mediated CFTR gene therapy to the upper and lower airways of patients with CF.
Pediatric Pulmonology
46(suppl. 46):
S34.
Excoffon KJDA,
Koerber JT,
Dickey DD et al.
(2009)
Directed evolution of adeno‐associated virus to an infectious respiratory virus.
Proceedings of the National Academy of Sciences of the USA
106(10):
3865–3870.
Flotte TR,
Afione SA,
Solow R et al.
(1993)
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno‐associated virus promoter.
Journal of Biological Chemistry
268(5):
3781–3790.
Flotte TR,
Zeitlin PL,
Reynolds TC et al.
(2003)
Phase I trial of intranasal and endobronchial administration of a recombinant adeno‐associated virus serotype 2 (rAAV2)‐CFTR vector in adult cystic fibrosis patients: a two‐part clinical study.
Human Gene Therapy
14(11):
1079–1088.
Gill DR,
Southern KW,
Mofford KA et al.
(1997)
A placebo‐controlled study of liposome‐mediated gene transfer to the nasal epithelium of patients with cystic fibrosis.
Gene Therapy
4(3):
199–209.
Griesenbach U and
Alton EWFW
(2013)
Expert opinion in biological therapy: update on developments in lung gene therapy.
Expert Opinion on Biological Therapy
13(3):
345–360.
Griesenbach U,
Inoue M,
Meng C et al.
(2012)
Assessment of F/HN‐pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
American Journal of Respiratory and Critical Care Medicine
186(9):
846–856.
Halbert CL,
Standaert TA,
Wilson CB and
Miller AD
(1998)
Successful readministration of adeno‐associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure.
Journal of Virology
72(12):
9795–9805.
Harvey BG,
Leopold PL,
Hackett NR et al.
(1999)
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.
Journal of Clinical Investigation
104(9):
1245–1255.
Hay JG,
McElvaney NG,
Herena J and
Crystal RG
(1995)
Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.
Human Gene Therapy
6(11):
1487–1496.
Hemmi H,
Takeuchi O,
Kawai T et al.
(2000)
A Toll‐like receptor recognizes bacterial DNA.
Nature
408(6813):
740–745.
Hyde SC,
Pringle IA,
Abdullah S et al.
(2008)
CpG‐free plasmids confer reduced inflammation and sustained pulmonary gene expression.
Nature Biotechnology
26(5):
549–551.
Hyde SC,
Southern KW,
Gileadi U et al.
(2000)
Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis.
Gene Therapy
7(13):
1156–1165.
Joseph PM,
O'Sullivan BP,
Lapey A et al.
(2001)
Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
Human Gene Therapy
12(11):
1369–1382.
Knowles MR,
Hohneker KW,
Zhou Z et al.
(1995)
A controlled study of adenoviral‐vector‐mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.
New England Journal of Medicine
333(13):
823–831.
Konstan MW,
Davis PB,
Wagener JS et al.
(2004)
Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.
Human Gene Therapy
15(12):
1255–1269.
Lee TWR and
Southern KW
(2013)
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystif fibrosis‐related lung disease.
Cochrane Database of Systematic Reviews
11:
1–39 (Art No.: CD005599).
Li C,
Diprimio N,
Bowles DE et al.
(2012)
Single amino acid modification of adeno‐associated virus capsid changes transduction and humoral immune profiles.
Journal of Virology
86(15):
7752–7759.
Li X,
Rossen N,
Sinn PL et al.
(2013)
Integrin α6β4 identifies human distal lung epithelial progenitor cells with potential as a cell‐based therapy for cystic fibrosis lung disease.
PLoS One
8(12):
e83624.
Limberis MP,
Vandenberghe LH,
Zhang L,
Pickles RJ and
Wilson JM
(2009)
Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.
Molecular Therapy
17(2):
294–301.
Moss RB,
Milla C,
Colombo J et al.
(2007)
Repeated aerosolized AAV‐CFTR for treatment of cystic fibrosis: a randomized placebo‐controlled phase 2B trial.
Human Gene Therapy
18(8):
726–732.
Moss RB,
Rodman D,
Spencer LT et al.
(2004)
Repeated adeno‐associated virus serotype 2 aerosol‐mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double‐blind, placebo‐controlled trial.
Chest
125(2):
509–521.
Noone PG,
Hohneker KW,
Zhou Z et al.
(2000)
Safety and biological efficacy of a lipid‐CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis.
Molecular Therapy
1(1):
105–114.
Ong T and
Ramsey BW
(2013)
Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Current Opinion in Pulmonary Medicine
19:
645–651.
O'Sullivan BP and
Freedman SD
(2009)
Cystic fibrosis.
The Lancet
373:
1891–1904.
Perricone MA,
Morris JE,
Pavelka K et al.
(2001)
Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium.
Human Gene Therapy
12(11):
1383–1394.
Pettit RS
(2012)
Cystic fibrosis transmembrance conductance regulator‐modifying medications.
Annals of Pharmacotherapy
46(7):
1065–1075.
Porteous DJ,
Dorin JR,
McLachlan G et al.
(1997)
Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
Gene Therapy
4(3):
210–218.
Pringle IA,
Hyde SC and
Gill DR
(2009)
Non‐viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
Expert Opinion on Biological Therapy
9(8):
991–1003.
Riordan JR,
Rommens JM,
Kerem BS et al.
(1989)
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Science
245(4922):
1066–1073;
erratum Science 245(4925): 1437.
Rogan MP,
Stoltz DA and
Hornick DB
(2011)
Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation‐specific treatment.
Chest
139(6):
1480–1490.
Rowe SM and
Verkman AS
(2013)
Cystic fibrosis transmembrane regulator correctors and potentiators.
Cold Spring Harbor Perspecitves in Medicine
3:
a009761.
Ruiz FE,
Clancy JP,
Perricone MA et al.
(2001)
A clinical inflammatory syndrome attributable to aerosolized lipid‐DNA administration in cystic fibrosis.
Human Gene Therapy
12(7):
751–761.
Sinn PL,
Arias AC,
Brogden KA and
McCray PB Jr
(2008)
Lentivirus vector can be readministered to nasal epithelia without blocking immune responses.
Journal of Virology
82(21):
10684–10692.
Stocker AG,
Kremer KL,
Koldej R et al.
(2009)
Single‐dose lentiviral gene transfer for lifetime airway gene expression.
Journal of Gene Medicine
11(10):
861–867.
UK Cystic Fibrosis Registry
(2013)
Annual Data Report 2012: Summary.
London, UK: Cystic Fibrosis Trust.
Wagner JA,
Messner AH,
Moran ML et al.
(1999)
Safety and biological efficacy of an adeno‐associated virus vector‐cystic fibrosis transmembrane regulator (AAV‐CFTR) in the cystic fibrosis maxillary sinus.
Laryngoscope
109(2 Part 1):
266–274.
Wagner JA,
Nepomuceno IB,
Messner AH et al.
(2002)
A phase II, double‐blind, randomized, placebo‐controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.
Human Gene Therapy
13(11):
1349–1359.
Yan Z,
Keiser NW,
Song Y et al.
(2013)
A novel chimeric adenoassociated cirus 2/human Bocavirus 1 parvovirus vector efficiently transduces human airway epithelia.
Molecular Therapy
21(12):
2181–2194.
Zabner J,
Cheng SH,
Meeker D et al.
(1997)
Comparison of DNA‐lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo.
Journal of Clinical Investigation
100(6):
1529–1537.
Zabner J,
Couture LA,
Gregory RJ et al.
(1993)
Adenovirus‐mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.
Cell
75(2):
207–216.
Zabner J,
Ramsey BW,
Meeker DP et al.
(1996)
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.
Journal of Clinical Investigation
97(6):
1504–1111.
Zhang LN,
Karp P,
Gerard CJ et al.
(2004)
Dual therapeutic utility of proteasome modulating agents for pharmaco‐gene therapy of the cystic fibrosis airway.
Molecular Therapy
10(6):
990–1002.
Zielenski J
(2000)
Genotype and phenotype in cystic fibrosis.
Respiration
67(2):
117–133.
Zuckerman JB,
Robinson CB,
McCoy KS et al.
(1999)
A phase I study of adenovirus‐mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis.
Human Gene Therapy
10(18):
2973–2985.
Further Reading
Brunetti‐Pierri N and
Ng P
(2008)
Progress and prospects: gene therapy for genetic diseases with helper‐dependent adenoviral vectors.
Gene Therapy
15(8):
533–560.
Burney TJ and
Davies JC
(2012)
Gene therapy for the treatment of cystic fibrosis.
Application of Clinical Genetics
5:
29–36.
Griesenbach T and
Alton EWFW
(2013)
Moving forward: cystic fibrosis gene therapy.
Human Molecular Genetics
22:
R52–R58.
Kwon I and
Schaffer DV
(2008)
Designer gene delivery vectors: molecular engineering and evolution of adeno‐associated viral vectors for enhanced gene transfer.
Pharmaceutical Research
25(3):
489–499.
Lobeck CC
(2000)
Cystic fibrosis.
In: Scriver CR (ed.)
The Metabolic and Molecular Bases of Inherited Disease,
8th edn,
pp. 1605–1626.
New York, NY: McGraw‐Hill.
Web Links
Cystic Fibrosis Mutation Database, Statistics (accessed on 10 Nov 2013). http://www.genet.sickkids.on.ca
Cystic Fibrosis Transmembrane Conductance Regulator, ATP‐Binding Cassette (Sub‐family C, Member 7) (CFTR); MIM: 602421. GeneLink. http://www.ncbi.nlm.nih.gov/gene/1080